Furthermore, combination treatment with FTD/TPI and bevacizumab among metastatic CRC patients refractory to standard therapies exerted promising effects with manageable safety in a phase I/II clinical trial, regardless of KRAS status [10] and in fact, bevacizumab showed an additive effect to FTD/TPI monotherapy in a Denmark study [11]. This evidence concerns the gene KRAS and colorectal carcinoma.